trending Market Intelligence /marketintelligence/en/news-insights/trending/JaQbP_8UP8wH9MBs3_-53g2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Japan IP court rules in Lilly's favor on Alimta patents

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity


Japan IP court rules in Lilly's favor on Alimta patents

The Japan IP High Court ruled in favor of Eli Lilly & Co. in the invalidation trials initiated by Sawai Pharmaceutical Co. Ltd. regarding Lilly's vitamin regimen patents for Alimta.

The ruling has confirmed the decision of the Japanese Patent Office made in 2015, which upheld the validity of the Alimta vitamin regimen patents.

If the patents are upheld through all challenges, they could provide intellectual property protection for Alimta in Japan until June 2021. Lilly will take necessary actions to defend and enforce the patents.